> For the complete documentation index, see [llms.txt](https://docs.finngen.fi/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://docs.finngen.fi/finngen-data-specifics/disease-specific-task-forces-and-interest-groups/inflammatory-bowel-disease-ibd-task-force.md).

# Inflammatory bowel disease (IBD) Task Force

Chairs: Mark Daly (FinnGen), Jukka Koskela (FinnGen), Amy Hart (J\&J)

Secretary: Elisa Lahtela (FinnGen)

**Main scientific questions**

* Can we define the genetics of disease progression?
  * Create definitions of progression (also severity, remission, therapeutic response) using hard endpoints of surgery and hospitalization as well as disease behavior, quantitative clinical biomarkers (Fcal, CRP, …), medication switching, etc.
  * Perform GWAS and compare genetics of progression to the established genetics of incidence
* Can we use proteomics to define medication and progression signatures?
  * Using definitions defined in aim 1
  * Collect multiple time points at/before diagnosis and during disease progression

All Task Force related summary statistics can be found from: /finngen/library-green/task\_force/

All Task Force GWASes can be found from Task Force PheWeb: <https://results.taskforce.finngen.fi/>

More detailed Scientific proposal, meeting materials and analysis documentation can be found in [Teams here](https://helsinkifi.sharepoint.com/:f:/s/FinnGen150/EreJeL5V8ypHtzvpPnQlcTEBm2wDth2udndJxxSZWnKRRQ?e=tO3Dwa)

{% content-ref url="/pages/KVfzW9Ph6zCgKJuYlBk2" %}
[How do I join the FinnGen Teams group?](/faq/about-finngen-access-and-accounts/how-do-i-join-the-finngen-teams-group.md)
{% endcontent-ref %}

If you don't have access to the Teams Group, write to <finngen-admin@helsinki.fi>.